# DESCRIPTION

## TECHNICAL FIELD

- relate to agent for enhancing action of anticancer drugs

## BACKGROUND ART

- introduce HDACs and their inhibitors

## DISCLOSURE OF INVENTION

### Technical Problem

- describe limitations of combined use of anticancer drugs

### Solution to Problem

- hypothesize HDACi regulates antioxidation mechanism
- investigate HDAC1 and RFP
- reveal HDAC1 downregulates TBP-2 expression
- reveal RFP is recruited to TBP-2 promoter
- reveal suppression of RFP enhances action of anticancer drug
- reveal RFP correlates with poor prognosis in cancer patients

### Advantageous Effects of Invention

- describe improved clinical outcomes of therapy

## DESCRIPTION OF EMBODIMENTS

### (Action Enhancing Agent of Anticancer Drugs and Use Thereof)

- introduce action enhancing agent of anticancer drugs
- motivate oxidative stress-inducing ability
- define enhance action of anticancer drugs
- describe examples of anticancer drugs
- reveal HDAC1 accelerates resistance of cancer cells
- motivate targeting RFP to increase sensitivity of cancer cells
- define RFP and its functions
- describe compound for suppressing expression of RFP gene
- explain RNAi and its application
- describe design and preparation of siRNA
- provide examples of siRNA sequences
- describe nucleic acid construct for generating siRNA
- introduce action enhancing agent
- describe antisense method
- explain antisense nucleic acid
- discuss hybridization performance
- describe modification of antisense nucleic acid
- explain use of promoter
- describe ribozyme method
- explain construction of ribozyme
- describe compound suppressing RFP action
- explain antibody as active ingredient
- describe formulation of agent
- explain dosage form and administration
- describe use in combination with anticancer drugs
- list target cancers

### (Method for Testing Anticancer Drug Resistance)

- motivate anticancer drug resistance testing
- introduce RFP gene expression method
- describe detection step
- explain expression amount calculation
- detail immunohistochemistry method
- outline antibody preparation and use
- describe determination step
- provide evaluation examples
- discuss treatment policy determination
- summarize benefits of testing method

### <Example 1>

- illustrate evaluation division example

### <Example 2>

- illustrate evaluation division example

### (Biomarker for Estimating Prognosis and Use Thereof)

- motivate biomarker for prognosis estimation
- describe prognosis estimation method
- outline reagent and kit for prognosis estimation

### <Example 1>

- illustrate evaluation division example

### <Example 2>

- illustrate evaluation division example
- describe prognosis estimation based on RFP expression
- outline reagent and kit for prognosis estimation

## EXAMPLES

- describe experiments based on hypothesis

### 1. Materials and Methods

- introduce plasmids
- describe RNAi
- generate cell lines stably expressing shRNA
- describe cell viability assay
- describe RT-PCR
- describe immunoprecipitation and Western blotting

### 2. Results and Discussion

- test effect of HDACi on cellular sensitivity to oxidative stress
- investigate molecular mechanism underlying sensitization
- determine binding domain of RFP and HDAC1
- knockdown RFP or HDAC1 to enhance sensitivity to H2O2 and cisplatin
- identify target genes repressed by HDAC1 and RFP
- confirm TBP-2 expression is transcriptionally regulated by HDAC1 and RFP
- test whether TBP-2 sensitizes cells to H2O2 and cisplatin
- examine recruitment of HDAC1 and RFP to TBP-2 promoter region
- investigate interaction between HDAC1, RFP, and NF-Y
- study effect of RFP expression on in vivo anticancer drug treatment models
- analyze effect of RFP expression on prognosis of cancer patients

## INDUSTRIAL APPLICABILITY

- describe application of action enhancing agent in cancer treatment

